Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581698 · ClinicalTrials.gov registry record
Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 876
- Enrollment target
NCT00581698: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00581698 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 876 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00581698 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 876 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether we can consistently identify the first lymph node (the "sentinel node") draining your melanoma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 876 participants |
| Start Date | 1991-01 |
| Est. Completion | 2009-09 |
What the finished NCT00581698 record still lists
NCT00581698 is an observational study that tracks outcomes without assigning an intervention. The registered 876 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00581698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00581698 about?
NCT00581698 is a clinical study titled "Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue". The purpose of this study is to determine whether we can consistently identify the first lymph node (the "sentinel node") draining your melanoma.
What is the current status of trial NCT00581698?
This trial is currently completed. The enrollment target is 876 participants. The study started on 1991-01. Estimated completion is 2009-09.
Who is sponsoring clinical trial NCT00581698?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07076199 · 877 participants · Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- NCT06627647 · 878 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia